Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Study to Characterize the Effects of the Spiegelmer® NOX H94 on Anemia of Chronic Disease in Patients With Cancer

NCT01691040 is registered in ClinicalTrials.gov with TME Pharma AG as lead sponsor.

NCT NCT01691040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01691040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Study to Characterize the Effects of the Spiegelmer® NOX H94 on Anemia of Chronic Disease in Patients With Cancer
Lead sponsor
TME Pharma AG
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2012
Completion date
December 31, 2013
Enrollment
12 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic disease